Providing clinicians and patients with actual prognosis: Cancer in the context of competing causes of death

Journal of the National Cancer Institute - Monographs

Volumn 2014, Issue 49, 2014, Pages 255-264

  Howlader, Nadia ^a   Mariotto, Angela B ^a   Woloshin, Steven ^b,c,d   Schwartz, Lisa M ^b,c,d  

^a NATIONAL CANCER INSTITUTE   (United States)

^b DARTMOUTH INSTITUTE FOR HEALTH POLICY AND CLINICAL PRACTICE   (United States)

^c NORRIS COTTON CANCER CENTER   (United States)

^d VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER REGISTRY; CANCER STAGING; CAUSE OF DEATH; COLON CANCER; COLORECTAL CANCER; COMORBIDITY; CONTROLLED STUDY; FEMALE; HEALTH CARE PERSONNEL; HUMAN; ICD-O-3; LUNG CANCER; MALE; MIDDLE AGED; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; UNITED STATES; VERY ELDERLY; BREAST TUMOR; COLON TUMOR; LUNG TUMOR; MORTALITY; PROGNOSIS; PROSTATE TUMOR; RISK ASSESSMENT; SURVIVAL RATE; YOUNG ADULT;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CAUSE OF DEATH; COLONIC NEOPLASMS; COMORBIDITY; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSTATIC NEOPLASMS; RISK ASSESSMENT; SEER PROGRAM; SURVIVAL RATE; UNITED STATES; YOUNG ADULT;

EID: 84938595155     PISSN: 10526773     EISSN: 17456614     Source Type: Book Series    
DOI: 10.1093/jncimonographs/lgu022     Document Type: Article

References (27)

1. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2010. Bethesda, MD: National Cancer Institute; 2013. http://seer. cancer.gov/csr/1975_2010/. Published April 2013. Accessed June 17, 2013.
2. Ederer F, Axtell LM, Cutler SJ. The relative survival rate: a statistical methodology. Natl Cancer Inst Monogr. 1961;6:101-121.
3. Marubini E VM. Analysing Survival Data From Clinical Trials and Observational Studies. Chichester, UK: John Wiley & Sons; 1995.
4. Cho H, Mariotto AB, Mann BS, Klabunde CN, Feuer EJ. Assessing noncancer-related health status of US cancer patients: other-cause survival and comorbidity prevalence. Am J Epidemiol. 2013;178(3):339-349.
5. Esserman L, Shieh Y, Thompson I. Rethinking screening for breast cancer and prostate cancer. JAMA. 2009;302(15):1685-1692.
6. Welch HG, Albertsen PC, Nease RF, Bubolz TA, Wasson JH. Estimating treatment benefits for the elderly: the effect of competing risks. Ann Intern Med. 1996;124(6):577-584.
7. Edwards BK, Noone AM, Mariotto AB, et al. Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer. 2014;120(9):1290-1314.
8. Cronin KA, Feuer EJ. Cumulative cause-specific mortality for cancer patients in the presence of other causes: a crude analogue of relative survival. Stat Med. 2000;19(13):1729-1740.
9. Schairer C, Mink PJ, Carroll L, Devesa SS. Probabilities of death from breast cancer and other causes among female breast cancer patients. J Natl Cancer Inst. 2004;96(17):1311-1321.
10. Howlader N, Ries LA, Mariotto AB, Reichman ME, Ruhl J, Cronin KA. Improved estimates of cancer-specific survival rates from population-based data. J Natl Cancer Inst. 2010;102(20):1584-1598.
11. Baili P, Micheli A, De Angelis R, et al. Life tables for world-wide comparison of relative survival for cancer (CONCORD study). Tumori. 2008;94(5):658-668.
12. Coleman MP, Quaresma M, Berrino F, et al. Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol. 2008;9(8):730-756.
13. SEER cause-specific death classification. Surveillance, Epidemiology, and End Results Program Web site. http://seer.cancer.gov/causespecific/. Accessed June 17, 2013.
14. Localized/regional/distant stage adjustments: for 1973-2009 SEER research data (November 2011 submission) and later releases. Surveillance, Epidemiology, and End Results Program Web site. http://seer.cancer.gov/seerstat/variables/seer/yr1973_2009/lrd_stage/index.html. Accessed June 17, 2013.
15. Klabunde CN, Legler JM, Warren JL, Baldwin LM, Schrag D. A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. Ann Epidemiol. 2007;17(8):584-590.
16. Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000;53(12):1258-1267.
17. Mariotto AB, Wang Z, Klabunde CN, Cho H, Das B, Feuer EJ. Life tables adjusted for comorbidity more accurately estimate noncancer survival for recently diagnosed cancer patients. J Clin Epidemiol. 2013;66(12):1376-1385.
18. SEER*Stat software [computer program]. Version 7.0.4. Bethesda, MD: Surveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute; 2010.
19. Albertsen PC, Moore DF, Shih W, Lin Y, Li H, Lu-Yao GL. Impact of comorbidity on survival among men with localized prostate cancer. J Clin Oncol. 2011;29(10):1335-1341.
20. Daskivich TJ, Fan KH, Koyama T, et al. Effect of age, tumor risk, and comorbidity on competing risks for survival in a U.S. population-based cohort of men with prostate cancer. Ann Intern Med. 2013;158(10):709-717.
21. Feuer EJ, Lee M, Mariotto AB, et al. The Cancer Survival Query System: making survival estimates from the Surveillance, Epidemiology, and End Results program more timely and relevant for recently diagnosed patients. Cancer. 2012;118(22):5652-5662.
22. Feuer EJ, Rabin B, Zou Z, et al. The Surveillance, Epidemiology, and End Results Cancer Survival Calculator SEER*CSC: validation in a managed care setting. J Natl Cancer Inst Monogr. 2014;49:265-274.
23. Begg CB, Schrag D. Attribution of deaths following cancer treatment. J Natl Cancer Inst. 2002;94(14):1044-1045.
24. Percy C, Stanek E 3rd, Gloeckler L. Accuracy of cancer death certificates and its effect on cancer mortality statistics. Am J Public Health. 1981;71(3):242-250.
25. Rabin BA, Ellis JL, Steiner JF, et al. Health-care utilization by prognosis profile in a managed care setting: using the Surveillance, Epidemiology, and End Results Cancer Survival Calculator SEER*CSC. J Natl Cancer Inst Monogr. 2014;49:265-274.
26. Rabin BA, Gaglio B, Sanders T, et al. Predicting cancer prognosis using interactive online tools: a systematic review and implications for cancer care providers. Cancer Epidemiol Biomarkers Prev. 2013;22(10):1645-1656.
27. Gulati R, Inoue LYT, Gore JL, et al. Individualized estimates of overdiagnosis in screen-detected prostate cancer. J Natl Cancer Inst. (2014);106(2):djt367. doi:10.1093/jnci/djt367.